Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

40
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
40
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

31
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
31
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

27
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
27
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

39
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
39
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

1.2K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.2K
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

30
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
30

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Multiscale Dissolution Simulation of Particles from a Tablet in Dissolution Apparatus by Coupling Discrete Element with Lattice Boltzmann Methods.

Pharmaceutical research·2026
Same author

Evaluation of a Novel Flexible Cage System for C5-C6 Fixation: A Finite Element Study Against Conventional ACDF Implants.

Bioengineering (Basel, Switzerland)·2026
Same author

Editorial: Integrated diagnostics and biomarker discovery in endocrinology and biomedical sciences, volume II.

Frontiers in endocrinology·2025
Same author

Recent advances in polymer-based drug delivery systems for atopic dermatitis: enhancing therapeutic efficacy and outcomes.

Materials today. Bio·2025
Same author

Challenges and innovations in long-acting injectable formulations: can formulation design space be rationalized?

The Journal of pharmacy and pharmacology·2025
Same author

Long-Acting injectable buprenorphine PLGA microparticle formulation.

International journal of pharmaceutics·2025

Video Experimental Relacionado

Updated: Feb 19, 2026

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

8.2K

Formulaciones de implantes sólidos compactados para la administración a largo plazo de buprenorfina

Andrew Otte1, Kinam Park1

  • 1Purdue University, Weldon School of Biomedical Engineering, West Lafayette, IN 47907, USA.

Journal of controlled release : official journal of the Controlled Release Society
|February 17, 2026
PubMed
Resumen
Este resumen es generado por máquina.

Nuevos implantes biodegradables ofrecen liberación sostenida de buprenorfina durante más de tres meses, lo que podría mejorar la adherencia al tratamiento y los resultados para el trastorno por uso de opioides (TUO). Este avance en las formulaciones de acción prolongada aborda una necesidad crítica en el manejo del TUO.

Palabras clave:
BuprenorfinaFormulación de varilla compactadaInyectables de acción prolongadaTrastorno por uso de opioidesVarillas de PLGA

Más Videos Relacionados

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
04:13

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models

Published on: September 27, 2024

898
Fate Mapping of Human Embryonic Stem Cells by Teratoma Formation
08:56

Fate Mapping of Human Embryonic Stem Cells by Teratoma Formation

Published on: August 1, 2010

17.9K

Videos de Experimentos Relacionados

Last Updated: Feb 19, 2026

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

8.2K
Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
04:13

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models

Published on: September 27, 2024

898
Fate Mapping of Human Embryonic Stem Cells by Teratoma Formation
08:56

Fate Mapping of Human Embryonic Stem Cells by Teratoma Formation

Published on: August 1, 2010

17.9K

Área de la Ciencia:

  • Farmacología; Ciencia de Materiales; Sistemas de Administración de Fármacos

Sus antecedentes:

  • El trastorno por uso de opioides (TUO) es un problema de salud pública importante en los EE. UU. El tratamiento asistido por medicamentos con buprenorfina es una estrategia clave de manejo. Los productos existentes de buprenorfina de acción prolongada ofrecen liberación durante 1 semana o 1 mes.

Objetivo del estudio:

  • Desarrollar nuevas formulaciones de varillas biodegradables de poli(lactida-co-glicolida) (PLGA) para la liberación sostenida de buprenorfina. Lograr la liberación del fármaco durante un período de tres meses o más. Minimizar la liberación inicial común en los sistemas de PLGA.

Principales métodos:

  • La base libre de buprenorfina y el PLGA se compactaron térmicamente en varillas sólidas utilizando un plastómetro. La fabricación implicó temperaturas de 165-180 °C y cargas de compresión de 4-16 kg. Se realizaron estudios farmacocinéticos in vivo en modelos de ratas y perros.

Principales resultados:

  • Desarrollamos implantes de varillas de PLGA que contenían 70% p/p de buprenorfina. Se minimizó la liberación inicial optimizando la compactación, reduciendo la formación de poros. Se demostraron concentraciones plasmáticas sostenidas de buprenorfina que superan los tres meses en modelos animales.

Conclusiones:

  • Las nuevas varillas biodegradables de PLGA proporcionan una liberación sostenida de buprenorfina durante ≥3 meses. Estos implantes de acción prolongada representan un avance prometedor para el tratamiento del TUO. Potencial para mejorar la adherencia del paciente y mejorar los resultados clínicos en el manejo del TUO.